Trial Profile
Randomised trial of anti-CD20 in CD4+ chronic allograft nephropathy
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 12 Mar 2007
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 12 Mar 2007 New trial record.